Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$11.07 - $16.04 $24.7 Million - $35.8 Million
-2,232,139 Reduced 65.74%
1,163,356 $13.8 Million
Q4 2022

Feb 14, 2023

BUY
$4.2 - $14.24 $14.3 Million - $48.4 Million
3,395,495 New
3,395,495 $23 Million

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $250M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Tcg Crossover Management, LLC Portfolio

Follow Tcg Crossover Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tcg Crossover Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tcg Crossover Management, LLC with notifications on news.